

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

---

Objective Drug Reviews Since 1959

---

Volume 57

October 12, 2015

ISSUE No.

1479

### IN THIS ISSUE

**Addendum: PCV13 for Adults 65 Years and Older** .....p 144

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws.  
Forwarding, copying or any other distribution of this material is strictly prohibited.  
For further information call: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Objective Drug Reviews Since 1959

Volume 57 (Issue 1479)

October 12, 2015

### Addendum: PCV13 for Adults 65 Years and Older (Med Lett Drugs Ther 2014; 56:102)

In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal conjugate vaccine (PCV13) followed 6 to 12 months later by the pneumococcal polysaccharide vaccine (PPSV23). In June 2015, the ACIP changed the recommended interval between the two vaccines to >1 year for immunocompetent adults ≥65 years old (MMWR Morbid Mortal Wkly Rep 2015; 674:944). Separating the vaccines by a year or more may improve the immune response to the serotypes in both vaccines. If a dose of PPSV23 is given earlier than the recommended interval, it does not need to be repeated.

Follow us on Twitter  Like us on Facebook 

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.; **EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR:** Jean-Marie Pflomm, Pharm.D.; **ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D., Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.; **SENIOR ASSOCIATE EDITOR:** Amy Faucard

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; Jane P. Gagliardi, M.D., M.H.S., F.A.C.P., Duke University School of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR:** Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue; **EDITORIAL ASSISTANT:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona; **FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski; **DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. is supported solely by subscription fees and accepts no advertising, grants, or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

**Subscriptions (US):**  
1 year - \$129; 2 years - \$232;  
3 years - \$345. \$65 per year  
for students, interns, residents, and  
fellows in the US and Canada.  
Reprints - \$12 each.

**Site License Inquiries:**  
E-mail: info@medicalletter.org  
Call: 800-211-2769 ext. 315  
Special rates available for bulk  
subscriptions.

Copyright 2015. ISSN 1523-2859

Get Connected:  